AR100073A1 - HETEROCYCLIC SULPHONES REPLACED WITH HETEROARILES - Google Patents

HETEROCYCLIC SULPHONES REPLACED WITH HETEROARILES

Info

Publication number
AR100073A1
AR100073A1 ARP150101120A ARP150101120A AR100073A1 AR 100073 A1 AR100073 A1 AR 100073A1 AR P150101120 A ARP150101120 A AR P150101120A AR P150101120 A ARP150101120 A AR P150101120A AR 100073 A1 AR100073 A1 AR 100073A1
Authority
AR
Argentina
Prior art keywords
alkyl
heterocyclyl
cycloalkyl
heteroaryl
aryl
Prior art date
Application number
ARP150101120A
Other languages
Spanish (es)
Inventor
Dr Schunk Stefan
Dr Reich Melanie
Dr Jakob Florian
Dr Damann Nils
Dr Haurand Michael
Dr Kless Achim
Dr Rogers Marc
Dr Sutton Kathy
Original Assignee
Gruenenthal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal Gmbh filed Critical Gruenenthal Gmbh
Publication of AR100073A1 publication Critical patent/AR100073A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

Compuestos útiles como bloqueadores de los canales de calcio activados por el voltaje (CaV). Composiciones farmacéuticas que las contienen. Su uso en el tratamiento y/o la profilaxis del dolor y de otras enfermedades y/o trastornos. Reivindicación 1: Un compuesto caracterizado porque es de fórmula general (1), donde m representa 0, 1 ó 2; n denota 0 ó 1; Y se selecciona entre el grupo que consiste en un enlace y -C(R³)₂-; donde cada R³ se selecciona en forma independiente entre el grupo que consiste en H y C₁₋₆-alquilo, o dos R³ forman junto con el átomo de C que los conecta un C₃₋₁₀-cicloalquilo o un heterociclilo de entre 3 y 7 miembros; L es -[C(R⁴)₂]ˣ-(X)ʸ-[C(R⁴)₂]ᶻ-, donde x es 0, 1 ó 2, y es 0 ó 1 y z es 0 ó 1, con la condición de que x ³ y; cada R⁴ se selecciona en forma independiente entre el grupo que consiste en H y C₁₋₆-alquilo, o dos R⁴ forman junto con el átomo de C que los conecta un C₃₋₁₀-cicloalquilo o un heterociclilo de entre 3 y 7 miembros o dos R⁴ forman junto con dos átomos de C adyacentes que los conectan un C₃₋₁₀-cicloalquilo o un heterociclilo de entre 3 y 7 miembros; X se selecciona entre el grupo que consiste en O, S, S(O)₂, N(H) o N(C₁₋₆-alquilo); R¹ se selecciona entre el grupo que consiste en H; F; Cl; CN; C₁₋₆-alquilo; C₁₋₆-alquil-O(R⁵) y C₁₋₆-alquil-N(R⁵)₂; donde cada R⁵ se selecciona en forma independiente entre H o C₁₋₆-alquilo o dos R⁵ forman junto con el átomo de N que los conecta un heterociclilo de entre 3 y 7 miembros; R² se selecciona entre el grupo que consiste en H; F; Cl; CN; C₁₋₆-alquilo; C₁₋₆-alquil-O(R⁶) y C₁₋₆-alquil-N(R⁶)₂; donde cada R⁶ se selecciona en forma independiente entre H o C₁₋₆-alquilo o dos R⁶ forman junto con el átomo de N que los conecta un heterociclilo de entre 3 y 7 miembros; Ar¹ representa arilo o heteroarilo, donde dicho arilo o dicho heteroarilo está sustituido con cero o uno o dos o tres sustituyentes R⁷; Ar² representa heteroarilo, sustituido con cero o uno o dos o tres sustituyentes R⁸; donde cada R⁷ y cada R⁸ se selecciona en forma independiente entre el grupo que consiste en F; Cl; Br; I; NO₂; CN; C₁₋₆-alquilo; CF₃; CF₂H; CFH₂; CF₂Cl; CFCl₂; C(=O)-H; C(=O)-C₁₋₆-alquilo; C(=O)-OH; C(=O)-O-C₁₋₆-alquilo; C(=O)-N(H)(OH); C(=O)-NH₂; C(=O)-N(H)(C₁₋₆-alquilo); C(=O)-N(C₁₋₆-alquilo)₂; C(=N-OH)-H; C(=N-OH)-C₁₋₆-alquilo; C(=N-O-C₁₋₆-alquil)-H; C(=N-O-C₁₋₆-alquil)-C₁₋₆-alquilo; OH; OCF₃; OCF₂H; OCFH₂; OCF₂Cl; OCFCl₂; O-C₁₋₆-alquilo; O-C(=O)-C₁₋₆-alquilo; O-C(=O)-O-C₁₋₆-alquilo; O-(C=O)-N(H)(C₁₋₆-alquilo); O-C(=O)-N(C₁₋₆-alquilo)₂; O-S(=O)₂-C₁₋₆-alquilo; O-S(=O)₂-OH; O-S(=O)₂-O-C₁₋₆-alquilo; O-S(=O)₂-NH₂; O-S(=O)₂-N(H)(C₁₋₆-alquilo); O-S(=O)₂-N(C₁₋₆-alquilo)₂; NH₂; N(H)(C₁₋₆-alquilo); N(C₁₋₆-alquilo)₂; N(H)-C(=O)-C₁₋₆-alquilo; N(H)-C(=O)-O-C₁₋₆-alquilo; N(H)-C(=O)-NH₂; N(H)-C(=O)-N(H)(C₁₋₆-alquilo); N(H)-C(=O)-N(C₁₋₆-alquilo)₂; N(C₁₋₆-alquil)-C(=O)-C₁₋₆-alquilo; N(C₁₋₆-alquil)-C(=O)-O-C₁₋₆-alquilo; N(C₁₋₆-alquil)-C(=O)-NH₂; N(C₁₋₆-alquil)-C(=O)-N(H)(C₁₋₆-alquilo); N(C₁₋₆-alquil)-C(=O)-N(C₁₋₆-alquilo)₂; N(H)-S(=O)₂OH; N(H)-S(=O)₂-C₁₋₆-alquilo; N(H)-S(=O)₂-O-C₁₋₆-alquilo; N(H)-S(=O)₂-NH₂; N(H)-S(=O)₂-N(H)(C₁₋₆-alquilo); N(H)-S(=O)₂N(C₁₋₆-alquilo)₂; N(C₁₋₆-alquil)-S(=O)₂-OH; N(C₁₋₆-alquil)-S(=O)₂-C₁₋₆-alquilo; N(C₁₋₆ alquil)-S(=O)₂-O-C₁₋₆-alquilo; N(C₁₋₆-alquil)-S(=O)₂-NH₂; N(C₁₋₆-alquil)-S(=O)₂-N(H)(C₁₋₆-alquilo); N(C₁₋₆-alquil)-S(=O)₂-N(C₁₋₆-alquilo)₂; SH; SCF₃; SCF₂H; SCFH₂; SCF₂Cl; SCFCl₂; S-C₁₋₆-alquilo; S(=O)-C₁₋₆-alquilo; S(=O)₂-C₁₋₆-alquilo; S(=O)₂-OH; S(=O)₂-O-C₁₋₆-alquilo; S(=O)₂-NH₂; S(=O)₂-N(H)(C₁₋₆-alquilo); S(=O)₂-N(C₁₋₆ alquilo)₂; C₃₋₁₀-cicloalquilo; heterociclilo de entre 3 y 7 miembros; arilo; heteroarilo; O-C₃₋₁₀-cicloalquilo; O-(heterociclilo de entre 3 y 7 miembros); O-arilo; O-heteroarilo; N(H)-C₃₋₁₀-cicloalquilo; N(H)-(heterociclilo de entre 3 y 7 miembros); N(H)-arilo; N(H)-heteroarilo; N(C₁₋₆-alquil)-C₃₋₁₀ cicloalquilo: N(C₁₋₆-alquil)-(heterociclilo de entre 3 y 7 miembros); N(C₁₋₆-alquil)-arilo; N(C₁₋₆-alquil)-heteroarilo; C(=O)-C₃₋₁₀-cicloalquilo; C(=O)-(heterociclilo de entre 3 y 7 miembros); C(=O)-arilo; C(=O)-heteroarilo; S(=O)₂-C₃₋₁₀-cicloalquilo; S(=O)₂-(heterociclilo de entre 3 y 7 miembros); S(=O)₂-arilo; S(=O)₂-heteroarilo; S(=O)(=NR¹³)-C₃₋₁₀-cicloalquilo; S(=O)(=NR¹³)-(heterociclilo de entre 3 y 7 miembros); S(=O)(=NR¹³)-arilo y S(=O)(=NR¹³)-heteroarilo, donde R¹³ representa H o C₁₋₆-alquilo; donde en cada caso dicho C₁₋₆-alquilo puede ser ramificado o lineal; no sustituido o monosustituido o polisustituido; y donde en cada caso dicho C₃₋₁₀-cicloalquilo, heterociclilo de entre 3 y 7 miembros, arilo y heteroarilo puede no estar sustituido o estar monosustituido o polisustituido; opcionalmente en forma de un estereoisómero aislado o una mezcla de estereoisómeros, en forma del compuesto libre y/o una sal aceptable para uso fisiológico y/o un solvato aceptable para uso fisiológico del mismo.Useful compounds as calcium channel blockers activated by voltage (CaV). Pharmaceutical compositions that contain them. Its use in the treatment and / or prophylaxis of pain and other diseases and / or disorders. Claim 1: A compound characterized in that it is of the general formula (1), where m represents 0, 1 or 2; n denotes 0 or 1; And it is selected from the group consisting of a bond and -C (R³) ₂-; where each R³ is independently selected from the group consisting of H and C₁₋₆-alkyl, or two R³ together with the C atom connecting them a C₃₋₁₀-cycloalkyl or a heterocyclyl of 3 to 7 members ; L is - [C (R⁴) ₂] ˣ- (X) ʸ- [C (R⁴) ₂] ᶻ-, where x is 0, 1 or 2, and is 0 or 1 and z is 0 or 1, with the condition that x ³ y; each R⁴ is independently selected from the group consisting of H and C₁₋₆-alkyl, or two R⁴ together with the C atom that connects them with a C₃₋₁₀-cycloalkyl or a heterocyclyl of between 3 and 7 members or two R⁴s together with two adjacent C atoms that connect them with a C₃₋₁₀-cycloalkyl or a heterocyclyl of 3 to 7 members; X is selected from the group consisting of O, S, S (O) ₂, N (H) or N (C₁₋₆-alkyl); R¹ is selected from the group consisting of H; F; Cl; CN; C₁₋₆-alkyl; C₁₋₆-alkyl-O (R⁵) and C₁₋₆-alkyl-N (R⁵) ₂; where each R⁵ is independently selected from H or C₁₋₆-alkyl or two R⁵ together with the N atom connecting them a heterocyclyl of 3 to 7 members; R² is selected from the group consisting of H; F; Cl; CN; C₁₋₆-alkyl; C₁₋₆-alkyl-O (R⁶) and C₁₋₆-alkyl-N (R⁶) ₂; where each R⁶ is independently selected from H or C₁₋₆-alkyl or two R⁶ together with the N atom connecting them a heterocyclyl of 3 to 7 members; Ar¹ represents aryl or heteroaryl, wherein said aryl or said heteroaryl is substituted with zero or one or two or three R⁷ substituents; Ar² represents heteroaryl, substituted with zero or one or two or three substituents R⁸; where each R⁷ and each R⁸ is independently selected from the group consisting of F; Cl; Br; I; NO₂; CN; C₁₋₆-alkyl; CF₃; CF₂H; CFH₂; CF₂Cl; CFCl₂; C (= O) -H; C (= O) -C₁₋₆-alkyl; C (= O) -OH; C (= O) -O-C₁₋₆-alkyl; C (= O) -N (H) (OH); C (= O) -NH₂; C (= O) -N (H) (C₁₋₆-alkyl); C (= O) -N (C₁₋₆-alkyl) ₂; C (= N-OH) -H; C (= N-OH) -C₁₋₆-alkyl; C (= N-O-C₁₋₆-alkyl) -H; C (= N-O-C₁₋₆-alkyl) -C₁₋₆-alkyl; OH; OCF₃; OCF₂H; OCFH₂; OCF₂Cl; OCFCl₂; O-C₁₋₆-alkyl; O-C (= O) -C₁₋₆-alkyl; O-C (= O) -O-C₁₋₆-alkyl; O- (C = O) -N (H) (C₁₋₆-alkyl); O-C (= O) -N (C₁₋₆-alkyl) ₂; O-S (= O) ₂-C₁₋₆-alkyl; O-S (= O) ₂-OH; O-S (= O) ₂-O-C₁₋₆-alkyl; O-S (= O) ₂-NH₂; O-S (= O) ₂-N (H) (C₁₋₆-alkyl); O-S (= O) ₂-N (C₁₋₆-alkyl) ₂; NH₂; N (H) (C₁₋₆-alkyl); N (C₁₋₆-alkyl) ₂; N (H) -C (= O) -C₁₋₆-alkyl; N (H) -C (= O) -O-C₁₋₆-alkyl; N (H) -C (= O) -NH₂; N (H) -C (= O) -N (H) (C₁₋₆-alkyl); N (H) -C (= O) -N (C₁₋₆-alkyl) ₂; N (C₁₋₆-alkyl) -C (= O) -C₁₋₆-alkyl; N (C₁₋₆-alkyl) -C (= O) -O-C₁₋₆-alkyl; N (C₁₋₆-alkyl) -C (= O) -NH₂; N (C₁₋₆-alkyl) -C (= O) -N (H) (C₁₋₆-alkyl); N (C₁₋₆-alkyl) -C (= O) -N (C₁₋₆-alkyl) ₂; N (H) -S (= O) ₂OH; N (H) -S (= O) ₂-C₁₋₆-alkyl; N (H) -S (= O) ₂-O-C₁₋₆-alkyl; N (H) -S (= O) ₂-NH₂; N (H) -S (= O) ₂-N (H) (C₁₋₆-alkyl); N (H) -S (= O) ₂N (C₁₋₆-alkyl) ₂; N (C₁₋₆-alkyl) -S (= O) ₂-OH; N (C₁₋₆-alkyl) -S (= O) ₂-C₁₋₆-alkyl; N (C₁₋₆ alkyl) -S (= O) ₂-O-C₁₋₆-alkyl; N (C₁₋₆-alkyl) -S (= O) ₂-NH₂; N (C₁₋₆-alkyl) -S (= O) ₂-N (H) (C₁₋₆-alkyl); N (C₁₋₆-alkyl) -S (= O) ₂-N (C₁₋₆-alkyl) ₂; SH; SCF₃; SCF₂H; SCFH₂; SCF₂Cl; SCFCl₂; S-C₁₋₆-alkyl; S (= O) -C₁₋₆-alkyl; S (= O) ₂-C₁₋₆-alkyl; S (= O) ₂-OH; S (= O) ₂-O-C₁₋₆-alkyl; S (= O) ₂-NH₂; S (= O) ₂-N (H) (C₁₋₆-alkyl); S (= O) ₂-N (C₁₋₆ alkyl) ₂; C₃₋₁₀-cycloalkyl; 3 to 7 member heterocyclyl; aryl; heteroaryl; O-C₃₋₁₀-cycloalkyl; O- (3 to 7 member heterocyclyl); O-aryl; O-heteroaryl; N (H) -C₃₋₁₀-cycloalkyl; N (H) - (3- to 7-membered heterocyclyl); N (H) -aryl; N (H) -heteroaryl; N (C₁₋₆-alkyl) -C₃₋₁₀ cycloalkyl: N (C₁₋₆-alkyl) - (heterocyclyl of 3 to 7 members); N (C₁₋₆-alkyl) -aryl; N (C₁₋₆-alkyl) -heteroaryl; C (= O) -C₃₋₁₀-cycloalkyl; C (= O) - (heterocyclyl of 3 to 7 members); C (= O) -aryl; C (= O) -heteroaryl; S (= O) ₂-C₃₋₁₀-cycloalkyl; S (= O) ₂- (heterocyclyl of 3 to 7 members); S (= O) ₂-aryl; S (= O) ₂-heteroaryl; S (= O) (= NR¹³) -C₃₋₁₀-cycloalkyl; S (= O) (= NR¹³) - (heterocyclyl of 3 to 7 members); S (= O) (= NR¹³) -aryl and S (= O) (= NR¹³) -heteroaryl, where R¹³ represents H or C₁₋₆-alkyl; where in each case said C₁₋₆-alkyl can be branched or linear; not substituted or monosubstituted or polysubstituted; and where in each case said C₃₋₁₀-cycloalkyl, 3- and 7-membered heterocyclyl, aryl and heteroaryl may not be substituted or be monosubstituted or polysubstituted; optionally in the form of an isolated stereoisomer or a mixture of stereoisomers, in the form of the free compound and / or a salt acceptable for physiological use and / or a solvate acceptable for physiological use thereof.

ARP150101120A 2014-04-14 2015-04-14 HETEROCYCLIC SULPHONES REPLACED WITH HETEROARILES AR100073A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14001346 2014-04-14

Publications (1)

Publication Number Publication Date
AR100073A1 true AR100073A1 (en) 2016-09-07

Family

ID=50486704

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150101120A AR100073A1 (en) 2014-04-14 2015-04-14 HETEROCYCLIC SULPHONES REPLACED WITH HETEROARILES

Country Status (16)

Country Link
US (2) US9879000B2 (en)
EP (2) EP3131894A1 (en)
JP (1) JP6673850B2 (en)
KR (1) KR20160144487A (en)
CN (1) CN106458956B (en)
AR (1) AR100073A1 (en)
AU (1) AU2015246387B2 (en)
BR (1) BR112016023860A2 (en)
CA (1) CA2945535A1 (en)
CL (1) CL2016002615A1 (en)
EA (1) EA032581B1 (en)
IL (1) IL248250A0 (en)
MX (1) MX2016013447A (en)
PE (1) PE20161366A1 (en)
TW (1) TW201620899A (en)
WO (1) WO2015158427A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
CA2945529A1 (en) 2014-04-14 2015-10-22 Grunenthal Gmbh Aryl substituted heterocyclyl sulfones
TW201718557A (en) * 2015-10-08 2017-06-01 歌林達有限公司 Pyrazolyl substituted tetrahydropyranylsulfones
TW201726128A (en) 2015-10-08 2017-08-01 歌林達有限公司 Pyrazolyl substituted tetrahydropyranylsulfones
CA2968836A1 (en) 2016-06-13 2017-12-13 Gilead Sciences, Inc. Fxr (nr1h4) modulating compounds
ES2921432T3 (en) 2016-06-13 2022-08-25 Gilead Sciences Inc Azetidine derivatives as modulators of FXR (NR1H4)
PL3600309T3 (en) 2017-03-28 2022-11-07 Gilead Sciences, Inc. Therapeutic combinations for treating liver diseases
CA3116141C (en) 2018-12-06 2023-09-05 Daiichi Sankyo Company, Limited Cycloalkane-1,3-diamine derivative
CA3124702A1 (en) 2019-01-15 2020-07-23 Gilead Sciences, Inc. Fxr (nr1h4) modulating compounds
JP2022519906A (en) 2019-02-19 2022-03-25 ギリアード サイエンシーズ， インコーポレイテッド Solid form of FXR agonist
EP4045487A1 (en) * 2019-10-18 2022-08-24 Fmc Corporation Methods for the preparation of 5-bromo-2-(3-chloro-pyridin-2-yl)-2h-pyrazole-3-carboxylic acid
HUE062047T2 (en) * 2019-10-18 2023-09-28 Fmc Corp Methods for the preparation of 5-bromo-2-(3-chloro-pyridin-2-yl)-2h-pyrazole-3-carboxylic acid

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1138680A1 (en) * 2000-03-29 2001-10-04 Pfizer Products Inc. Gem substituted sulfonyl hydroxamic acids as MMP inhibitors
WO2007125398A2 (en) 2006-04-27 2007-11-08 Pfizer Japan Inc. : sulfonamide compounds as antagonists of the n-type calcium channel
GB0813142D0 (en) * 2008-07-17 2008-08-27 Glaxo Group Ltd Novel compounds
NZ598269A (en) * 2009-09-18 2014-12-24 Zalicus Pharmaceuticals Ltd Aryl sulphone derivatives as calcium channel blockers
CA2945529A1 (en) 2014-04-14 2015-10-22 Grunenthal Gmbh Aryl substituted heterocyclyl sulfones
TW201718557A (en) 2015-10-08 2017-06-01 歌林達有限公司 Pyrazolyl substituted tetrahydropyranylsulfones
TW201726128A (en) 2015-10-08 2017-08-01 歌林達有限公司 Pyrazolyl substituted tetrahydropyranylsulfones

Also Published As

Publication number Publication date
US20150291572A1 (en) 2015-10-15
BR112016023860A2 (en) 2017-08-15
KR20160144487A (en) 2016-12-16
CN106458956A (en) 2017-02-22
US20170121314A1 (en) 2017-05-04
CN106458956B (en) 2019-06-14
AU2015246387A1 (en) 2016-12-01
CA2945535A1 (en) 2015-10-22
EP3495360A1 (en) 2019-06-12
US9879000B2 (en) 2018-01-30
AU2015246387B2 (en) 2018-11-22
JP6673850B2 (en) 2020-03-25
WO2015158427A1 (en) 2015-10-22
TW201620899A (en) 2016-06-16
EP3131894A1 (en) 2017-02-22
MX2016013447A (en) 2017-01-18
US9926302B2 (en) 2018-03-27
EA032581B1 (en) 2019-06-28
PE20161366A1 (en) 2017-01-15
CL2016002615A1 (en) 2017-04-28
IL248250A0 (en) 2016-11-30
EA201692049A1 (en) 2017-04-28
JP2017511352A (en) 2017-04-20

Similar Documents

Publication Publication Date Title
AR100073A1 (en) HETEROCYCLIC SULPHONES REPLACED WITH HETEROARILES
AR097325A1 (en) RINGED PIRROLS
AR106296A1 (en) TETRAHYDROPIRANILSULPHONES REPLACED WITH PIRAZOLILO
AR106763A1 (en) OXADIAZOLS REPLACED TO FIGHT FITOPATHOGEN FUNGI
AR095192A1 (en) QUINOLINA AND QUINAZOLINAMIDAS AS MODULAR SODIUM CHANNELS
AR106755A2 (en) PYROLIC INHIBITORS OF THE QUINASA ERK PROTEIN, SYNTHESIS AND INTERMEDIARIES OF THE SAME
AR088535A1 (en) DERIVATIVES OF AMIDAS OF REPLACED AMINO ACIDS WITH N-UREA AS FORMUL RECEPTOR MODULATORS PEPTIDE RECEIVER OF TYPE 1 RECEPTOR (FPRL-1)
AR083879A1 (en) ANTIBACTERIAL AMINOGLYCOSID ANALOGS, METHODS OF PREPARATION AND USE AS THERAPEUTIC AGENTS
AR110088A1 (en) MAGL INHIBITORS
UY36121A (en) ? PIRAZOLOPIRIDINAS AND PIRAZOLOPIRIMIDINAS ?.
AR048939A1 (en) DERIVATIVES OF PHENOL AND THIOPHENOL 3 - OR 4 - USEFUL MONOSUSTITUTES AS LIGANDOS OF H3; PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USE IN THE MANUFACTURE OF MEDICINES FOR THE TREATMENT OF NEUROLOGICAL AND INFLAMMATORY DISORDERS.
AR063118A1 (en) DERIVATIVES OF SULFONAMIDE-PIPERIDINE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USES IN ALLERGIC AND RESPIRATORY INFLAMMATORY DISEASES AND DISORDERS
AR092279A1 (en) PIRROL CARBOXAMIDAS FLUOROMETILO REPLACED
AR069490A1 (en) GLUCOCORTICOID RECEPTORS AGONISTS
AR097079A1 (en) SALTS OF DERIVATIVES OF 2-AMINO-1-HYDROXYETYL-8-HYDROXYQUINOLIN-2 (1H) -ONE THAT HAVE ANTAGONIST ACTIVITY OF MUSCARINIC RECEPTORS AS WELL AS AGONIST ACTIVITY OF THE ADRENERICAL RECEIVER b2
AR107828A1 (en) 2-AMINO-N- [7-METOXI-2,3-DIHYDROIMIDAZO- [1,2-C] QUINAZOLIN-5-IL] PYRIMIDIN-5-CARBOXAMIDS AS A PI3K INHIBITOR
AR100714A1 (en) 1-OXA-4,9-DIAZAESPIRO UNDECANO COMPOUND RENTAL AND ARYL DERIVATIVES THAT HAVE MULTIMODAL ACTIVITY AGAINST PAIN
AR108906A1 (en) BIARILMETILE HETEROCICLES
AR111494A1 (en) ANILINOQUINAZOLINE C₅ COMPOUNDS AND ITS USE IN CANCER TREATMENT
AR119010A1 (en) COMPOUNDS, COMPOSITIONS AND METHODS OF USE
AR097199A1 (en) RORC2 INHIBITORS AND THEIR METHODS OF USE
AR099913A1 (en) DERIVATIVES OF INDOLIZINE, ITS PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
AR101196A1 (en) SUBSTITUTED PYRIMIDINE COMPOUNDS
AR118729A1 (en) SELECTIVE INHIBITOR OF JAK1 KINASE
UY37837A (en) NEW HETEROCYCLIC COMPOUNDS AS INHIBITORS OF CDK8 / 19

Legal Events

Date Code Title Description
FB Suspension of granting procedure